Published in
Taylor and Francis Group, Expert Review of Anticancer Therapy, 12(15), p. 1389-1403, 2015
DOI: 10.1586/14737140.2015.1115725
Links
Tools
Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1–derived oncolytic immunotherapy
Journal article published in 2015 by
Kevin J. Harrington 
,
Harrington Kj,
Igor Puzanov ,
J. Randolph Hecht,
Hecht Jr,
Hodi Fs,
F. Stephen Hodi,
Zsolt Szabo,
Swami Murugappan,
Kaufman Hl,
Howard L. Kaufman
,
Harrington Kj,
Igor Puzanov ,
J. Randolph Hecht,
Hecht Jr,
Hodi Fs,
F. Stephen Hodi,
Zsolt Szabo,
Swami Murugappan,
Kaufman Hl,
Howard L. Kaufman
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 